Ansun Biopharma, Inc.
11568 Sorrento Valley Road
About Ansun Biopharma, Inc.
Who We Are
Ansun is leading the development of novel therapeutics to address unmet needs in viral disease and cancer by using its industry-leading expertise in sialic acid biology.
We are industry veterans with significant drug discovery, development and commercialization expertise. We share a vision of developing innovative products to save lives, especially for vulnerable and underserved patients.
We focus our drug development programs to directly target unmet medical needs.
Our lead product, DAS181, is a sialidase fusion protein that removes the sialic acid present on the host cell surface that certain viruses use to enter the cell;it was conceived and designed using knowledge of virus and host interaction and sialic acid biology. DAS181 is now undergoing a Phase 3 clinical trial for the treatment of human Parainfluenza Virus (“PIV”) in immunocompromised patients.
Leveraging Ansun’s deep knowledge of sialic acid biology, we develop state-of-the-art multi-modality therapeutics for the treatment of cancer. This has led to programs including oncolytic virus, tumor microenvironment (TME)-modulating bispecific antibodies, and tumor-targeting CAR-NK/γδ T cells.